From a therapeutic perspective, these insights suggest that GPCR-targeted strategies—such as GLP-1 receptor agonists or bile acid-modulating agents—may hold potential for IBS management, although careful patient selection and safety considerations are required. The gene discussed is GLP1R; the disease is irritable bowel syndrome.